Visfatin, a New Adipocytokine, Is Predominantly Related to Inflammation/Endothelial Damage in Kidney Allograft Recipients

Transplantation Proceedings

Volumn 41, Issue 1, 2009, Pages 150-153

  Malyszko, J ^a   Malyszko, J S ^a   Mysliwiec, M ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ALBUMIN; ANTIPLASMIN; AZATHIOPRINE; C REACTIVE PROTEIN; CREATININE; CYCLOSPORIN A; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR; PREDNISONE; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADIPOSE TISSUE; ADULT; AGED; ARTICLE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENDOTHELIUM LESION; FEMALE; FIBRINOLYSIS; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY ALLOGRAFT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD COAGULATION; CYTOKINES; DIABETIC NEPHROPATHIES; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOLYSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; REFERENCE VALUES; TRANSPLANTATION, HOMOLOGOUS;

EID: 60649114315     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.10.086     Document Type: Article

References (23)

1. Guzik T.J., Mangalat D., and Korbut R. Adipocytokines-novel link between inflammation and vascular function?. J Physiol Pharmacol 57 (2006) 505
2. Zhang Y., Proenca R., Maffei M., et al. Positional cloning of the mouse obese and its human homologue. Nature 372 (1994) 425
3. Axelsson J., Bergsten A., Qureshi A.R., et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 69 (2006) 596
4. Fukuhara A., Matsuda M., Nishizawa M., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307 (2005) 426
5. Yilmaz M.I., Saglam M., Carrero J.J., et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 23 (2008) 959
6. Malyszko J., Malyszko J.S., Pawlak K., et al. Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure. Adv Med Sci 59 (2008) 32
7. Malyszko J., Malyszko J.S., Pawlak K., et al. The coagulo-lytic system and endothelial function in cyclosporine-treated kidney allograft recipients. Transplantation 62 (1996) 828
8. Pecoits-Filho R., Heimbürger O., Bárány P., et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 41 (2003) 1212
9. Samal B., Sun Y., Stearns G., et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14 (1994) 1431
10. Müller W.E., Perovic S., Wilkesman J., et al. Increased gene expression of a cytokine-related molecule and profilin after activation of Suberites domuncula cells with xenogeneic sponge molecule(s). DNA Cell Biol 18 (1999) 885
11. Moschen A.R., Kaser A., Enrich B., et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178 (2007) 1748
12. Kralisch S., Klein J., Lossner U., et al. Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 289 (2005) E586
13. Kim S.R., Bae Y.H., Bae S.K., et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta 1783 (2008) 886
14. Axelsson J., Witasp A., Carrero J.J., et al. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis 49 (2007) 237
15. Choi K.M., Lee J.S., Kim E.J., et al. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur J Endocrinol 158 (2008) 203
16. Alghasham A.A., and Barakat Y.A. Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy. Saudi Med J 29 (2008) 185
17. Retnakaran R., Youn B.S., Liu Y., et al. Correlation of circulating full-length visfatin (PBEF/Nampt) with metabolic parameters in subjects with and without diabetes: a cross-sectional study. Clin Endocrinol (Oxf) 69 (2008) 885
18. Malyszko J., Malyszko J.S., Pawlak K., et al. Resistin, a new adipokine, is related to inflammation and renal function in kidney allograft recipients. Transplant Proc 38 (2006) 3434
19. Samara A., Pfister M., Marie B., et al. Visfatin, low-grade inflammation and BMI. Clin Endocrinol (Oxf) 69 (2008) 568
20. Zhong M., Tan H.W., Gong H.P., et al. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf) 69 (2008) 878
21. Körner A., Garten A., Blüher M., et al. Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 92 (2007) 4783
22. Oki K., Yamane K., Kamei N., et al. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol (Oxf) 67 (2007) 796
23. Kato A., Odamaki M., Ishida J., et al. Relationship between serum pre-B cell colony-enhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients. Am J Nephrol 26 (2008) 31